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The purpose of this study is to clarify the significance of postoperative 
radiotherapy for N2 lung cancer. This study aimed to investigate the effect 
of postoperative radiotherapy on the survival and prognosis of patients 
with N2 lung cancer. Data from 12,000 patients with N2 lung cancer 
were extracted from the Surveillance, Epidemiology, and End Results 
database (2004-2012). Age at disease onset and 5-year survival rates were 
calculated. Survival curves were plotted using the Kaplan-Meier method. 
The univariate log-rank test was performed. Multivariate Cox regression 
were used to examine factors affecting survival. Patients’ median age was 
67 years (mean 66.46 ± 10.03). The 5-year survival rate was 12.55%. 
Univariate analysis revealed age, sex, pathology, and treatment regimen 
as factors affecting prognosis. In multivariate analysis, when compared to 
postoperative chemotherapy, postoperative chemoradiotherapy was better 
associated with survival benefits (hazard ratio [HR]= 0.85, 95% confidence 
interval [CI]: 0.813-0.898, P <0.001). Propensity score matching revealed 
that patients who had received postoperative chemoradiotherapy had 
a better prognosis than did patients who had received postoperative 
chemotherapy (HR=0.869, 95% CI: 0.817-0.925, P <0.001). Female 
patients and patients aged <65 years had a better prognosis than did their 
counterparts. Patients with adenocarcinoma had a better prognosis than 
did patients with squamous cell carcinoma. Moreover, prognosis worsened 
with increasing disease T stage. Patients who had received postoperative 
chemoradiotherapy had a better prognosis than did patients who had 
received postoperative chemotherapy. Postoperative radiotherapy was an 
independent prognostic factor in this patient group.
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1. Introduction
Lung cancer is a common cancer type and the leading 
cause of cancer-related deaths worldwide [1]. In 2018, there 
were 2.1 million new lung cancer cases and 1.8 million 
lung cancer-related deaths, accounting for 18.4% of all can-
cer-related deaths [2]. Non-small cell lung cancer (NSCLC) 
accounts for about 85% of lung cancer cases [3], among 
which adenocarcinoma and squamous cell carcinoma are the 
predominant types. Surgery is the standard treatment for NS-
CLC. Currently there are no guidelines on adjuvant treatment 
for patients with postoperative pathological N2 disease stage. 
Adjuvant chemotherapy is the standard treatment for patients 
with positive lymph node metastasis after operation, but there 
was a significant difference in whether adjuvant radiotherapy 
was performed.
2. Methods
The Surveillance, Epidemiology, and End Results 
(SEER) database was examined for data from lung can-
cer patients with a pathological diagnosis of NSCLC 
confirmed during 2004-2012. (Figure 1). Patients were 
included in the present study if they met the following cri-
teria: (1) Their postoperative stage was N2M0; (2) Squa-
mous cell carcinoma or adenocarcinoma was confirmed 
by pathology testing; (3) Postoperative treatment involved 
chemotherapy alone; (4) Diagnosis was confirmed during 
2004-2012.
Patients were excluded from the present study if they met 
any of the following criteria: (1) Unclear pathology results 
or confirmed diagnosis of a cancer type other than squamous 
cell carcinoma or adenocarcinoma; (2) Confirmed metasta-
sis; (3) Intraoperative or preoperative treatment with radio-
therapy; (4) No postoperative chemotherapy; (5) Confirmed 
multiple primary tumors; (6) Incomplete data.
Figure 1. schematic illustration
Statistical analysis
IBM SPSS statistics version 25 was used for statistical 
analysis. Chi-square test was used to analyze categor-
ical variables. Survival curves were plotted using the 
Kaplan-Meier method, and log-rank test was performed 
to analyze the differences in variables among groups. 
Differential variables were subjected to propensity score 
matching (PSM) in the postoperative chemoradiotherapy 
and postoperative chemotherapy group, and differences 
among groups were examined after matching. Univariate 
analysis was applied to compute models that included sex, 
stage, pathology, age, and treatment regimen. The varia-
bles that were significant in univariate analysis were in-
cluded in multivariate analysis. Cox proportional hazards 
model was used for multivariate analysis. P-values <0.05 
were considered statistically significant.
3. Results
Descriptive statistics
Among the 12,000 included patients. The age range 
was 19-95 years, with a median of 67 years (mean 66.46 ± 
10.03 years). There 6127 cases (51.06%) were T0-2, 5873 
cases (48.94%) were T3-4 (Table 1).
Table 1. Demographic and clinical characteristics of 
patients with squamous cell carcinoma and adenocarci-
noma included in the Surveillance, Epidemiology, and 
End Results (SEER) database











Squamous cell carcinoma 6652 55.43
Adenocarcinoma 5348 44.57
Age
≤ 65 years 5344 44.53
> 65 years 6656 55.47
Treatment
Postoperative chemoradiotherapy 2606 21.72
Postoperative chemotherapy 9394 78.28
Univariate analysis
Kaplan-Meier curves were plotted according to sex, 
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stage, pathology, age, and treatment regimen, revealing 
differences between groups. Women had a better progno-
sis than did men; patients aged 65 years and younger had 
a better prognosis than did patients older than 65 years; 
patients with adenocarcinoma had a better prognosis than 
did patients with squamous cell carcinoma; however, the 
prognosis worsened with increasing T stage. The progno-
sis of patients who had received postoperative chemoradi-
otherapy was better than that of patients who had received 
postoperative chemotherapy. There were statistically 
significant differences in gender, stage, pathology, age and 
treatment plan between groups (P < 0.01) (Figure 2).
Multivariate analyses
Multivariate analyses are carried out on the variables 
with significance of univariate analysis. Gender, T stage, 
pathology, age and treatment were included in the multi-
variate analysis. T stage was divided intoTt0-2 group and 
T3-4 group ,as shown in Table 2.
Table 2. Univariate and multivariate analyses
Group
    Univariate analysis Multivariate analysis
  P  OR  95% CI P  HR  95% CI
Sex < 0.001 1.434 1.236-1.663 < 0.001 1.131 1.085-1.178
Stage < 0.001 0.722 0.654-0.796 < 0.001 0.820 0.788-0.854
Pathology < 0.001 1.348 1.158-1.569 < 0.001 1.142 1.085-1.178
Age < 0.001 0.808 0.697-0.933 < 0.001 0.887 0.852-0.923
Treatment < 0.001 0.807 0.697-0.934 < 0.001 0.855 0.813-0.898
HR=hazard ratio
Figure 2. Kaplan-Meier curves of overall survival according to different groups. Survival difference of patients in group 
was statistically significant (p<0.001).
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Propensity score matching
After matching on sex, stage, pathology findings, and 
age, a total of 4,842 patients were included and divided 
evenly between the postoperative chemoradiotherapy 
(n=2421) and postoperative chemotherapy group (n = 
2421). The sample included 2,779 men and 2,063 wom-
en in. There were 21 cases at T0 stage, 1,091 cases at T1 
stage, 1,922 cases at T2 stage, 556 cases at T3 stage, and 
1,252 cases at T4 stage. There were 2,185 cases of squa-
mous cell carcinoma and 2,657 cases of adenocarcinoma. 
There were 2,300 patients aged 65 years or younger and 
2,542 patients older than 65 years. The age range was 
19-90 years, with a median of 66 years (mean 65.66 ± 
9.72). The 5-year survival rate and median survival time 
before and after matching are presented in Table 2. Be-
fore matching, the median survival time was 17 months, 
and the 5-year survival rate was 12.55%; after matching, 
the median survival time was 19 months, and the 5-year 
survival rate was 18.5%. The prognosis of patients who 
had received postoperative chemoradiotherapy was signif-
icantly better than that of patients who had received post-
operative chemotherapy alone (hazard ratio [HR]=0.869, 
95% confidence interval [CI]: 0.817-0.925, P <0.001). 
Treatment regimen was an independent prognostic factor 
for lung cancer patients (Table 3, and Figure 3 and 4).
Figure 3. Survival curve at mean of covariates
Figure 4. Significant difference survival curve of between 
after-matching PORT and NO-PORT (p<0.001).
Table 3. Survival outcomes for lung cancer patients included in the Surveillance, Epidemiology, and End Results (SEER) 
database, before and after propensity score matching
Group Before matching After matching
Cases Percentage (%) 5-year survival rate (%)
Median survival 






Male 7119 59.33 11.14 16 2779 57.39 15.87 17
Female 4881 40.67 14.61 18 2063 42.61 22.06 22
Stage
T0 66 0.55 30.30 37 21 0.43 38.10 28
T1 1640 13.67 19.02 23 1091 22.53 24.01 24
T2 4421 36.84 12.12 18 1922 39.69 18.21 20
T3 1842 15.35 12.87 16 556 11.48 16.19 11
T4 4031 33.59 9.95 14 1252 25.88 14.86 15
Pathology 
Squamous cell 
carcinoma 6652 55.43 10.34 15 2185 45.13 15.56 16
Adenocarcinoma 5348 44.57 15.30 19 2657 54.87 20.93 21
Age
≤ 65 years 5344 44.53 14.20 17 2300 47.50 20.04 20





2606 21.72 16.58 21 2421 50 20.12 21
Postoperative 
chemotherapy 9394 78.28 11.43 16 2421 50 16.89 17
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4. Discussion
NSCLC is a common type of lung cancer, of which 
adenocarcinoma and squamous cell carcinoma are the pre-
dominant subtypes. At the time of diagnosis, 30%-40% of 
patients have been reported to have disease at a locally ad-
vanced stage, accompanied by metastasis of cancer cells 
[4]. There are differences in the treatment of patients with 
N2 stage disease with mediastinal lymph node metastasis. 
Although comprehensive treatment is regarded as a stand-
ard regimen for N2 patients with resectable NSCLC, the 
optimal combination therapy regimen remains unclear [5]. 
Chemotherapy is required to treat resectable NSCLC [6,7]. 
Treatment regimens include radical concurrent chemoradi-
otherapy, induction chemotherapy or chemoradiotherapy, 
and postoperative chemotherapy or chemoradiotherapy. It 
remains unclear which regimen is optimal, but 5-year sur-
vival rate for any regimen is 20-45% [8]. Moreover, 5-year 
overall survival rates associated with micro-single-station, 
micro-multi-station, macro-single-station, and macro-mul-
ti-station involvement of mediastinal N2 lymph nodes 
have been reported as 34%, 11%, 8%, and 3%, respective-
ly [9]. Surgery alone is insufficient, and the survival rate 
of patients with operable locally-advanced NSCLC is not 
high [10]. It is increasingly believed that patients with N2 
disease stage should not be treated with surgery alone. In 
fact, evidence from randomized trials shows that adjuvant 
therapy is better than resection alone [11,12]. The guidelines 
on NCCN (National Comprehensive Cancer Network) 
treatment recommend that adjuvant chemotherapy or ad-
juvant chemoradiotherapy be performed for patients with 
disease stage N2. The present study examined differences 
in survival rates between patients with pN2 disease stage 
treated with chemotherapy alone and chemoradiotherapy.
There is little controversy around postoperative chemo-
therapy as a standard postoperative treatment for N2 
stage NSCLC with postoperative lymph node metastasis 
[13]. However, controversy surrounds administration of 
adjuvant radiotherapy. Based on data from the National 
Cancer Database (NCDB), Drake et al. have reported no 
difference in the median survival time between patients 
treated with adjuvant chemoradiotherapy and patients 
treated with adjuvant chemotherapy after R0 resection 
of disease at stage N0 and pathological N2 (3.9 years vs 
3.8 years, P = 0.705) [14]. Moreover, Spicer et al. have 
conducted a retrospective analysis of data from four chest 
tumor centers, and compared 5-year overall survival (OS) 
and disease-free survival (DFS) in patients treated with 
N2 postoperative chemotherapy and N2 postoperative 
concurrent chemoradiotherapy. Their study revealed no 
differences in recurrence rates, recurrence mode, perioper-
ative mortality, OS, or DFS in patients who had received 
preoperative invasive mediastinal staging [15].
It has been reported that postoperative radiotherapy 
can benefit pN2 patients. The American Thoracic Socie-
ty guidelines did not support administration of adjuvant 
radiotherapy for occult N2 (NSCLC) after RO resection. 
Postoperative radiotherapy increased the local control rate 
but did not improve the OS rate [16]. A meta-analysis of rel-
evant studies has shown that adjuvant radiotherapy lacked 
survival benefits after complete resection of NSCLC com-
pared with operation alone. In 2006, Lally et al., using 
the SEER data, argued that postoperative radiotherapy 
improved the survival rate of N2 patients but did not ben-
efit patients with disease stage N0 or N1 [17]. Douillard et 
al. have retrospectively analyzed data from pN2 patients 
who had received postoperative adjuvant radiotherapy, 
revealing that postoperative adjuvant radiotherapy gener-
ated more benefits but showed a negative effect on pN1 [18]. 
Based on data from the National Cancer Database, Hersk-
ovic et al. have conducted a stratified analysis to examine 
whether 2,691 patients with negative N2 ( Ⅲ A) resection 
margin who had received adjuvant chemotherapy during 
2004-2013 should receive postoperative radiotherapy. In 
their study, the median survival time was 27.43 months 
and 25.86 months (p <0.05), respectively. Postoperative 
radiotherapy significantly prolonged survival [19]. With im-
provements to radiotherapy technology, the local control 
rate increased, and treatment toxicity decreased [20]. More-
over, Su et al. have found that 1-year, 3-year, and 5-year 
OS rates associated with postoperative chemoradiotherapy 
and postoperative chemotherapy were 98.3% vs 86.1%, 
71.7% vs 53.0% and 45.7% vs 39.0%, respectively (P = 
0.019) [21].
In summary, there have been many studies aimed at 
examining the efficacy of N2 postoperative treatment 
regimens. In the present study, which involved analysis 
of data from the SEER database, we have shown that age, 
sex, disease stage, pathology type, and treatment regimen 
are factors that affect the prognosis of patients with N2 
lung cancer. In the present study, women and patients 
with adenocarcinoma had a better prognosis than did men 
and patients with squamous cell carcinoma. These find-
ings suggest that targeted therapy can be considered to 
prolong survival. Multivariate analysis has revealed that 
survival associated with postoperative chemoradiotherapy 
was longer than survival time associated with postopera-
tive chemotherapy alone. With the development of novel 
immunotherapy and targeted therapy regimens, further 
research is needed to identify the optimal postoperative 
treatment regimen for N2 lung cancer.
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5. Conclusions
It can be seen from this study that the prognosis of N2 
lung cancer is affected by many factors. Young, female 
and adenocarcinoma patients have more survival advan-
tages. With the increase of T stage, the prognosis is worse 
and worse. Postoperative adjuvant radiotherapy is better 
than postoperative chemotherapy alone.
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